Alpha and Beta Radiation for Theragnostics.

George Sgouros, Hong Song

Journal: PET clinics 2024;19(3):307-323

PMID: 38688775

Full Text on Elsevier Science View on PubMed

Abstract

Targeted radionuclide therapy (TRT) has significantly evolved from its beginnings with iodine-131 to employing carrier molecules with beta emitting isotopes like lutetium-177. With the success of Lu-177-DOTATATE for neuroendocrine tumors and Lu-177-PSMA-617 for prostate cancer, several other beta emitting radioisotopes, such as Cu-67 and Tb-161, are being explored for TRT. The field has also expanded into targeted alpha therapy (TAT) with agents like radium-223 for bone metastases in prostate cancer, and several other alpha emitter radioisotopes with carrier molecules, such as Ac-225, and Pb-212 under clinical trials. Despite these advancements, the scope of TRT in treating diverse solid tumors and integration with other therapies like immunotherapy remains under investigation. The success of antibody-drug conjugates further complements treatments with TRT, though challenges in treatment optimization continue.

Address: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 94305, USA. Electronic address: [email protected].; Division of Radiological Physics, Department of Radiology and Radiological Sciences, The Johns Hopkins University, Baltimore, MD 21205, USA.

DOI: 10.1016/j.cpet.2024.03.006

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-174

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Beta Particles, Alpha Particles, Radioisotopes, Radiopharmaceuticals, Neoplasms, Prostatic Neoplasms, Male, Lutetium, Radium, Bone Neoplasms